PD-1 Antibody and JAK1 Inhibitor for Newly Diagnosed Pediatric Hodgikin's Lympoma

Prior treatment

• Prior anti-tumor therapy for classic Hodgkin lymphoma (cHL);
• Inability to swallow oral medication, or any other factor affecting oral drug administration and absorption;
• Use of immunosuppressive agents, including systemic corticosteroids, within 14 days prior to study drug administration (use of ≤10 mg/day prednisone or equivalent is permitted);

Other illness

• Presence of any active, known, or suspected autoimmune disease (subjects who are in a stable condition and do not require systemic immunosuppressive therapy are permitted to enroll);
• History of other malignancies within the past 5 years;
• Any arterial thromboembolic event within the past 6 months, including myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack;
• Active hepatitis B or hepatitis C infection;
• History of stroke or intracranial hemorrhage within the past 6 months;
• Known history of human immunodeficiency virus (HIV) positivity.

Lab values

• Histopathologically confirmed nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL);
• Severe cardiac dysfunction with ejection fraction (EF) \<50%, or severe cardiac arrhythmia;

Other

• Patients with central nervous system (CNS) involvement by lymphoma;

• Age 6-18 years, male or female;
• Histologically confirmed classic Hodgkin lymphoma;
• Newly diagnosed, previously untreated patients;
• Subjects must have at least one measurable lesion, defined as: a lymph node lesion with the longest diameter \>1.5 cm on CT cross-sectional imaging; or an extranodal lesion with the longest diameter \>1.0 cm;
• ECOG performance status (PS) 0-2;
• Life expectancy ≥3 months;
• All screening laboratory tests must be performed as required by the protocol and within 7 days prior to enrollment. The laboratory values obtained at screening must meet the following criteria:
• Hematology (without blood transfusion, G-CSF, or medication to correct abnormalities within 14 days prior to screening):
  • Hemoglobin (Hb) ≥70 g/L;
  • Absolute neutrophil count (ANC) ≥0.5×10⁹/L;
  • Platelet count (PLT) ≥30×10⁹/L;
• Biochemistry:
  • Direct bilirubin (DBIL) \<2 × upper limit of normal (ULN);
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤5 × ULN;
  • Serum creatinine clearance ≥40 mL/min;
• The patient or his/her legal guardian has signed the informed consent form (ICF) and voluntarily agrees to participate in this study.